Chimeric antigen receptor T-cell therapy or CAR-T-cell therapy in short, which is developed by a company in Jiangning High-tech Zone, Nanjing, has been approved for marketing by the FDA of the USA. The first CAR-T-cell therapy product independently developed by China and to be marketed overseas will be used for the treatment of patients with relapsed or refractory multiple myeloma.
Nanjing Legend Biotechnology Co., Ltd.,a subsidiary of Genscript Biotech Corporation, has spent 7 years developing the CAR-T-cell therapy product or cilta-cel in short.
Ciltacabtagene autoleucel, an autologous chimeric antigen receptor T-cell therapy targeting B-cell maturation antigens, is custom-made using the patient's own T cells, which are harvested and genetically engineered, and then infused back into the patient.
Thanks to the original technology, the CAR-T-cell therapy product has achieved significant therapeutic effects in clinical research, and in 2020, it obtained the first-ever "Breakthrough Therapy" certification from the State Food and Drug Administration of China.
With CAR-T-cell therapy, Legend Bio has ranked first in the global immune cell therapy field. Jiangning Pharmaceutical Valley, which nurtures and supports the development of Legend Bio, has gathered more than 300 leading biopharmaceutical companies and high-growth projects, as well as nearly 10,000 medical and health professionals and innovative entrepreneurs.
